Peninsula biotech raises $35 million, looks to move quickly into late-stage mesothelioma trial
Peninsula biotech company Vivace Therapeutics has raised $35 million to push mesothelioma drug toward late-stage trial.
San Francisco’s AI sector fuels 2.4 million square feet of new office leases
When tech giants left San Francisco’s downtown towers, they drained the city’s energy. Now, AI firms — both giants and startups —are bringing it back.